Status:
UNKNOWN
HE4 is a Beneficial Biomarker in Endometrial Cancer
Lead Sponsor:
Ain Shams University
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
40-70 years
Brief Summary
Evaluation of Serum level of Human Epididymis Secretory Protein 4 (HE4) in Endometrial Cancer and clinical significant it
Detailed Description
.Endometrial cancer represents the most common gynecologic cancer, and it is expected to become an even greater public health concer as the prevalence of obesity, one of the most common risk factors f...
Eligibility Criteria
Inclusion
- Age (40 - 70 yr old).
Exclusion
- Age more than 70 yr and less than 40 yr.
- Abnormal cardiac hematological renal hepatic functions.
- Breast cancer or other malignancies.
- Concomitant benign and for malignant adnexal pathologies.
- Hormonal medication.
- Patient taking or having chemo-radiotherapy.
- Patients unfit for surgical intervention.
- Smoker.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2019
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT03459976
Start Date
December 1 2017
End Date
April 1 2019
Last Update
January 25 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University
Cairo, Abbasyia, Egypt, +20
2
Ain Shams University
Cairo, Abbasyia, Egypt, +20
3
Ain Shams University
Cairo, Egypt